In LLC-PK, porcine epithelial cells, the urokinase-type plasminogen activator (u-PA) mRNA and protein can be induced either by stimulation of the protein kinase C (PKC) pathway using a tumor promoter (PMA) or by stimulation of the protein kinase A (PKA) pathway with calcitonin SCT). By PKC, to LLC-P
Urokinase-type plasminogen activator stimulates wound healing in the diabetic mouse
✍ Scribed by P. A. Jimenez; M. Teliska; B. Liu; M. J. Antonaccio
- Publisher
- SP Birkhäuser Verlag Basel
- Year
- 1997
- Tongue
- English
- Weight
- 126 KB
- Volume
- 46
- Category
- Article
- ISSN
- 1420-908X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Mouse midlate placental development involves extensive tissue remodeling and cell invasion, processes which could be mediated by extracellular proteolytic enzymes. We have performed in situ expression analysis of urokinase type plasminogen activator (uPA), as well as functionally related molecules (
The urokinase-type plasminogen activator (u-PA) system consists of the serine proteinases plasmin and u-PA; the serpin inhibitors a 2 -anti-plasmin, PAI-1 and PAI-2; and the u-PA receptor (u-PAR). Two lines of evidence have strongly suggested an important and apparently causal role for the u-PA syst
## Abstract Calcitonin (CT) is synthesized and secreted in prostate epithelium, and its secretion from malignant prostates is several folds higher than that in benign prostates. CT receptor (CTR) is expressed in malignant prostate epithelium, and its activation increases invasiveness of prostate ca
## Background: The authors found previously that plasma levels of urokinase-type plasminogen activator (upa) and its receptor (upar) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. in the current study, they tested the hypothesi